Physiomics PLC Agreement with Bicycle and Cancer Research UK
08 Julho 2019 - 03:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
08 July 2019
8 July 2019
Physiomics plc
("Physiomics") or (the "Company")
Physiomics signs agreement with Bicycle Therapeutics and Cancer
Research UK
Physiomics plc (AIM: PYC), a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry, is pleased to announce that it has signed
an agreement to work with Bicycle Therapeutics and Cancer Research
UK. The project is expected to be completed during this calendar
year and will focus on the analysis of clinical data arising from
the ongoing Cancer Research UK-sponsored Phase I/IIa clinical trial
of Bicycle Therapeutics' lead program, BT1718, in solid
tumours.
Dr Jim Millen, CEO said: "We are very pleased to be working on
this second project with Bicycle Therapeutics and to be working for
the first time directly with Cancer Research UK, the UK's leading
cancer research charity."
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0) 20 7409 3494
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is a provider of technology-based
solutions to predict the effects of cancer treatment regimens for
the biopharma industry. The Company's Virtual Tumour(TM) technology
uses computer modelling to predict the effects of cancer drugs and
treatments to improve the success rate of drug discovery and
development projects while reducing time and cost. The predictive
capability of Physiomics' technologies have been confirmed by over
70 projects, involving over 30 targets and 60 drugs, and has worked
with clients such as Merck KGaA, Merck & Co, Bayer and
Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 120 years collectively of working in
oncology and/or computational biology and over 120 publications in
peer reviewed journals that have attracted thousands of
citations.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEADXSESPNEFF
(END) Dow Jones Newswires
July 08, 2019 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024